Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice
Preeti Raju, … , Sachiko Tsukita, Jerrold R. Turner
Preeti Raju, … , Sachiko Tsukita, Jerrold R. Turner
Published June 9, 2020
Citation Information: J Clin Invest. 2020;130(10):5197-5208. https://doi.org/10.1172/JCI138697.
View: Text | PDF
Research Article Cell biology Gastroenterology

Inactivation of paracellular cation-selective claudin-2 channels attenuates immune-mediated experimental colitis in mice

  • Text
  • PDF
Abstract

The tight junction protein claudin-2 is upregulated in disease. Although many studies have linked intestinal barrier loss to local and systemic disease, these have relied on macromolecular probes. In vitro analyses show, however, that these probes cannot be accommodated by size- and charge-selective claudin-2 channels. We sought to define the impact of claudin-2 channels on disease. Transgenic claudin-2 overexpression or IL-13–induced claudin-2 upregulation increased intestinal small cation permeability in vivo. IL-13 did not, however, affect permeability in claudin-2–knockout mice. Claudin-2 is therefore necessary and sufficient to effect size- and charge-selective permeability increases in vivo. In chronic disease, T cell transfer colitis severity was augmented or diminished in claudin-2–transgenic or –knockout mice, respectively. We translated the in vitro observation that casein kinase-2 (CK2) inhibition blocks claudin-2 channel function to prevent acute, IL-13–induced, claudin-2–mediated permeability increases in vivo. In chronic immune-mediated colitis, CK2 inhibition attenuated progression in claudin-2–sufficient, but not claudin-2–knockout, mice, i.e., the effect was claudin-2 dependent. Paracellular flux mediated by claudin-2 channels can therefore promote immune-mediated colitis progression. Although the mechanisms by which claudin-2 channels intensify disease remain to be defined, these data suggest that claudin-2 may be an accessible target in immune-mediated disorders, including inflammatory bowel disease.

Authors

Preeti Raju, Nitesh Shashikanth, Pei-Yun Tsai, Pawin Pongkorpsakol, Sandra Chanez-Paredes, Peter R. Steinhagen, Wei-Ting Kuo, Gurminder Singh, Sachiko Tsukita, Jerrold R. Turner

×

Figure 6

CK2 inhibition does not affect DSS colitis severity.

Options: View larger image (or click on image) Download as PowerPoint
CK2 inhibition does not affect DSS colitis severity.
(A) In vitro studie...
(A) In vitro studies have shown that casein kinase-2 (CK2) inhibition results in occludin S408 dephosphorylation. This increases occludin’s affinity for ZO-1 and leads to assembly of a trimolecular complex composed of occludin, ZO-1, and claudin-2 that inactivates claudin-2 channels (50). (B) Claudin-2 (CLDN2, green) expression in proximal colon of WT mice treated with vehicle or IL-13 without or with CK2 inhibition. Nuclei (blue) are shown for reference. Data are representative of 3 independent experiments. (C) Ussing chamber analysis of proximal colonic mucosal permeability to Na+ and 5 larger cations (methylamine, ethylamine, tetramethylammonium, tetraethylammonium, and N-methyl-D-glucamine), as in Figure 1. Both graphs show Cldn2+/+ mice treated with vehicle (circles) or IL-13 (squares). Mice that were treated with vehicle (left) or CK2 inhibitor (right) are shown in the 2 graphs. Data compiled from 3 independent experiments. ANOVA with Bonferroni’s correction. (D) Weight change of Cldn2+/+ and Cldn2–/– mice following DSS treatment without (circles) or with (diamonds) CK2 inhibitor. n = 5–7 per group. ANOVA with Bonferroni’s correction. (E) Representative pathology scores on day 8 after DSS treatment. n = 5–12 per group. ANOVA with Bonferroni’s correction. Data in D and E are representative of 4 independent experiments. *P < 0.05; **P < 0.01. Scale bars: 50 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts